Neurology Archives - Insights Get the latest news and education from Mayo Clinic Laboratories Mon, 02 Nov 2026 21:33:53 +0000 en-US hourly 1 https://wordpress.org/?v=7.1.4 How Mayo Clinic Advances Autoimmune Neurology Testing https://news.mayocliniclabs.com/2026/11/05/how-mayo-clinic-advances-autoimmune-neurology-testing/ https://news.mayocliniclabs.com/2026/11/05/how-mayo-clinic-advances-autoimmune-neurology-testing/#respond Thu, 05 Nov 2026 14:00:00 +0000 https://news.mayocliniclabs.com/?p=123801 How Mayo Clinic Advances Autoimmune Neurology TestingIn this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss a new collaboration and a Mayo Clinic-led study focused on detecting DNA mutations. Later, Dr. Pritt welcomes Andrew McKeon, M.B., B.Ch., M.D., and Anastasia Zekeridou, M.D., Ph.D., co-directors of Mayo Clinic’s Neuroimmunology Laboratory, to discuss how they are advancing patient care.

The post How Mayo Clinic Advances Autoimmune Neurology Testing appeared first on Insights.

]]>
https://news.mayocliniclabs.com/2026/11/05/how-mayo-clinic-advances-autoimmune-neurology-testing/feed/ 0
Autoimmune dysautonomia testing https://news.mayocliniclabs.com/2026/10/13/autoimmune-dysautonomia-testing/ https://news.mayocliniclabs.com/2026/10/13/autoimmune-dysautonomia-testing/#respond Tue, 13 Oct 2026 13:00:00 +0000 https://news.mayocliniclabs.com/?p=123408 Autoimmune dysautonomia testingBuilding on decades of leadership in autoimmune dysautonomia research, Mayo Clinic Laboratories has enhanced its dysautonomia antibody evaluation with a more sensitive, live cell-based flow cytometry method. The streamlined panel focuses on clinically relevant autoantibodies, providing physicians with actionable insights for diagnosis, prognosis, and treatment planning.

The post Autoimmune dysautonomia testing appeared first on Insights.

]]>
https://news.mayocliniclabs.com/2026/10/13/autoimmune-dysautonomia-testing/feed/ 0
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Diagnostic criteria https://news.mayocliniclabs.com/2026/09/28/myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mogad-2/ https://news.mayocliniclabs.com/2026/09/28/myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mogad-2/#respond Mon, 28 Sep 2026 10:00:00 +0000 https://news.mayocliniclabs.com/?p=123206 Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Diagnostic criteriaThis microlearning reviews myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), with a focus on the 2023 International MOGAD Panel diagnostic criteria.

The post Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Diagnostic criteria appeared first on Insights.

]]>
https://news.mayocliniclabs.com/2026/09/28/myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mogad-2/feed/ 0
Improve Alzheimer’s disease detection with innovative, FDA-cleared PrecivityAD2 blood biomarker testing https://news.mayocliniclabs.com/2026/09/15/improve-alzheimers-disease-detection-with-innovative-fda-cleared-precivityad2-blood-biomarker-testing/ https://news.mayocliniclabs.com/2026/09/15/improve-alzheimers-disease-detection-with-innovative-fda-cleared-precivityad2-blood-biomarker-testing/#respond Tue, 15 Sep 2026 13:00:00 +0000 https://news.mayocliniclabs.com/?p=123099 Improve Alzheimer’s disease detection with innovative, FDA-cleared PrecivityAD2 blood biomarker testingJoin Mayo Clinic Laboratories and C2N Diagnostics for our webinar exploring how the evolution of blood biomarker testing for Alzheimer's disease has expanded access to earlier, less-invasive diagnosis. Focusing on the newly FDA-cleared PrecivityAD2 blood test, which is offered by Mayo Clinic Laboratories in collaboration with C2N Diagnostics, the discussion will highlight how results from blood biomarker testing can support timely diagnosis, informed clinical decision-making, and improved patient care.

The post Improve Alzheimer’s disease detection with innovative, FDA-cleared PrecivityAD2 blood biomarker testing appeared first on Insights.

]]>
https://news.mayocliniclabs.com/2026/09/15/improve-alzheimers-disease-detection-with-innovative-fda-cleared-precivityad2-blood-biomarker-testing/feed/ 0
Comprehensive autoimmune/ paraneoplastic evaluations are critical in identifying coexisting antibodies https://news.mayocliniclabs.com/2026/09/09/comprehensive-autoimmune-paraneoplastic-evaluations-are-critical-in-identifying-coexisting-antibodies/ https://news.mayocliniclabs.com/2026/09/09/comprehensive-autoimmune-paraneoplastic-evaluations-are-critical-in-identifying-coexisting-antibodies/#respond Wed, 09 Sep 2026 13:00:00 +0000 https://news.mayocliniclabs.com/?p=121972 Comprehensive autoimmune/ paraneoplastic evaluations are critical in identifying coexisting antibodiesFind out how our autoimmune/paraneoplastic encephalopathy evaluations can identify multiple antibodies and guide the search for occult cancer.

The post Comprehensive autoimmune/ paraneoplastic evaluations are critical in identifying coexisting antibodies appeared first on Insights.

]]>
https://news.mayocliniclabs.com/2026/09/09/comprehensive-autoimmune-paraneoplastic-evaluations-are-critical-in-identifying-coexisting-antibodies/feed/ 0
UNC Health: Reducing redundant testing and achieving improved answers https://news.mayocliniclabs.com/2026/09/08/unc-health-reducing-redundant-testing-and-achieving-improved-answers/ https://news.mayocliniclabs.com/2026/09/08/unc-health-reducing-redundant-testing-and-achieving-improved-answers/#respond Tue, 08 Sep 2026 13:00:00 +0000 https://news.mayocliniclabs.com/?p=122791 UNC Health: Reducing redundant testing and achieving improved answersCollaborating with Mayo Clinic Laboratories, UNC Health streamlined neuroimmunology test ordering — eliminating outmoded testing and elevating diagnostic accuracy.

The post UNC Health: Reducing redundant testing and achieving improved answers appeared first on Insights.

]]>
https://news.mayocliniclabs.com/2026/09/08/unc-health-reducing-redundant-testing-and-achieving-improved-answers/feed/ 0
Unlock the Full Potential of Research Data https://news.mayocliniclabs.com/2026/09/03/unlock-the-full-potential-of-research-data/ https://news.mayocliniclabs.com/2026/09/03/unlock-the-full-potential-of-research-data/#respond Thu, 03 Sep 2026 13:00:00 +0000 https://news.mayocliniclabs.com/?p=123113 Unlock the Full Potential of Research DataIn this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss advancement in Alzheimer’s testing and practical uses of artificial intelligence (AI) in healthcare. Later, Dr. Pritt welcomes Chris Garcia, M.D., Mayo Clinic Laboratories’ chief digital innovation officer, to explore the evolving role of data in research and development.

The post Unlock the Full Potential of Research Data appeared first on Insights.

]]>
https://news.mayocliniclabs.com/2026/09/03/unlock-the-full-potential-of-research-data/feed/ 0
Nerve biopsy testing https://news.mayocliniclabs.com/2026/08/18/nerve-biopsy-testing/ https://news.mayocliniclabs.com/2026/08/18/nerve-biopsy-testing/#respond Tue, 18 Aug 2026 13:00:00 +0000 https://news.mayocliniclabs.com/?p=122892 Nerve biopsy testingLearn more about how Mayo Clinic’s Nerve Pathology Laboratory leverages decades of nerve pathology testing experience and unmatched clinical expertise to provide diagnostic clarity for rare and complex neuropathies.

The post Nerve biopsy testing appeared first on Insights.

]]>
https://news.mayocliniclabs.com/2026/08/18/nerve-biopsy-testing/feed/ 0
PDE10A autoimmunity presents as hyperkinetic movement disorder triggered by ICI treatment https://news.mayocliniclabs.com/2026/08/12/pde10a-autoimmunity-presents-as-hyperkinetic-movement-disorder-triggered-by-ici-treatment/ https://news.mayocliniclabs.com/2026/08/12/pde10a-autoimmunity-presents-as-hyperkinetic-movement-disorder-triggered-by-ici-treatment/#respond Wed, 12 Aug 2026 13:00:00 +0000 https://news.mayocliniclabs.com/?p=121808 PDE10A autoimmunity presents as hyperkinetic movement disorder triggered by ICI treatmentFind out how our suite of autoimmune movement disorder testing can help diagnose PDE10A autoimmunity in patients who present with hyperkinetic movement disorders.

The post PDE10A autoimmunity presents as hyperkinetic movement disorder triggered by ICI treatment appeared first on Insights.

]]>
https://news.mayocliniclabs.com/2026/08/12/pde10a-autoimmunity-presents-as-hyperkinetic-movement-disorder-triggered-by-ici-treatment/feed/ 0
Genome-wide methylation profiling brings new clarity to brain tumor diagnosis https://news.mayocliniclabs.com/2026/08/05/genome-wide-methylation-profiling-brings-new-clarity-to-brain-tumor-diagnosis/ https://news.mayocliniclabs.com/2026/08/05/genome-wide-methylation-profiling-brings-new-clarity-to-brain-tumor-diagnosis/#respond Wed, 05 Aug 2026 13:00:00 +0000 https://news.mayocliniclabs.com/?p=122533 Genome-wide methylation profiling brings new clarity to brain tumor diagnosisGenome-wide methylation profiling is transforming the way clinicians approach brain tumor diagnosis. By analyzing epigenetic patterns across the genome, this advanced testing method provides a new level of precision, helping resolve ambiguous cases, reduce diagnostic variability, and support more confident clinical decision-making in complex CNS tumors.

The post Genome-wide methylation profiling brings new clarity to brain tumor diagnosis appeared first on Insights.

]]>
https://news.mayocliniclabs.com/2026/08/05/genome-wide-methylation-profiling-brings-new-clarity-to-brain-tumor-diagnosis/feed/ 0